GBT’s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK
June 14, 2021 07:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to the discovery, development and...
New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
June 11, 2021 03:00 ET
|
Global Blood Therapeutics, Inc.
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the...
GBT Announces New Employment Inducement Grants
June 04, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on June 1, 2021, the compensation committee of GBT’s board of...
GBT Announces Participation at the Goldman Sachs 42nd Annual Global Healthcare Conference
June 01, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 42nd...
GBT kündigt Präsentation von Daten auf dem virtuellen Kongress der European Hematology Association (EHA) 2021 an
May 12, 2021 10:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Kalifornien, May 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) kündigte heute an, dass auf dem Virtuellen Kongress der European Hematology...
GBT présentera prochainement ses données à l’occasion du Congrès virtuel 2021 de l'Association européenne d'hématologie (EHA)
May 12, 2021 10:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Californie, 12 mai 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ : GBT) a annoncé aujourd'hui que six abstracts relatifs à son programme de...
GBT Announces Upcoming Data Presentations at European Hematology Association (EHA) 2021 Virtual Congress
May 12, 2021 10:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that six abstracts related to its sickle cell disease (SCD) programs...
GBT Announces New Employment Inducement Grants
May 07, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on May 1, 2021, the compensation committee of GBT’s board of...
GBT Announces Participation in Upcoming Investor Conferences
May 06, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following...
GBT Reports First Quarter 2021 Financial Results
May 05, 2021 16:05 ET
|
Global Blood Therapeutics, Inc.
Achieved Oxbryta® (voxelotor) net revenues of $39.0 million; on track with plans to potentially expand access to Oxbryta in the U.S. and Europe Advanced pipeline programs inclacumab and...